Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
15 Ergebnisse
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer. Non-small cell lung cancer ((NSCLC)) accounts for 80% to 85% of lung cancer. Most patients are locally
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing:
Ia: Type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections.
Ib. Patients' ability to drink the
FOLFIRINOX for 2nd-line Treatment of BTC
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells in a background of inflammatory cells. The majority of patients with HL have a good outcome with first-line chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine and
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
PRIMARY OBJECTIVES:
I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections.
II. To evaluate the safety and feasibility
Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Biliary tract carcinomas (BTCs) are invasive adenocarcinomas that arise from the epithelial cells of the biliary tree, which comprises intrahepatic and extrahepatic bile ducts, and the gallbladder. Even though BTCs are considered as rare tumors, they represent about 30% of the total primary liver
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Patients who meet the eligibility criteria and are randomized to one of the treatment arms, will receive either topotecan alone intravenously at 1.25 mg/m2 on days 1 to 5 of a 21-day cycle or pembrolizumab alone administered intravenously at 200mg every 21 days.
During the study period, patients
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Lung cancer is the leading cause of cancer-related mortality worldwide. A report published by the WHO in February 2014, estimated there were 1.83 million new cases and 1.59 million deaths worldwide in 2012. The American Lung Association reports 399,431 Americans living with lung cancer, with an
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
In the United States, the incidence of acute myeloid leukemia (AML) is approximately 3.5 cases per 100,000 persons per year. Approximately 13,000 people were diagnosed with AML in 2009 and 9,000 died of the disease, making AML the 6th leading cause of cancer death. Over the past three decades, AML
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
1. INDUCTION CHEMOTHERAPY
- For patients randomized to receive Idarubicin (Arm I, AI regimen) will be given Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) along with Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3).
- For patients randomized to receive
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
This is open-label, single center, 2-cohort phase I dose-escalation study of vandetanib administered orally on continuous daily dosing schedule + oral etoposide among adult patients with recurrent or relapsing malignant glioma. Patients will be stratified based on whether they are receiving EIAEDs &
A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
* TREATMENT PLANS FOR FIRST-LINE AND SECOND LINE CHEMOTHERAPY
1. First-line Chemotherapy 1.1 PACE and ACE Treatment Scheme of PACE and ACE* Cyclophosphamide 650 mg/m2, i.v. Day 1 Epirubicin 60 mg/m2, i.v. Day 1 Etoposide 55 mg/m2/d, i.v. Day 1-3 Prednisolone 60 mg/m2/d, p.o. Day 1-7
- For ACE,
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVES: I. Determine the efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing severe oral mucositis induced by total body irradiation and high dose chemotherapy in patients with hematologic malignancies. II. Compare the incidence of severe oral mucositis, the use of
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVES: I. Determine the efficacy of recombinant keratinocyte growth factor in reducing the duration of severe oral mucositis induced by total body irradiation and high dose chemotherapy in patients with hematologic malignancies. II. Determine the incidence and duration of severe oral mucositis,
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
